Distinguished Research Fellow
Director, Neglected Diseases Research
Dale Kempf has over 30 years of pharmaceutical R&D experience, mostly in antiviral and infectious diseases research. He is a co-inventor of AbbVie’s HIV protease inhibitors Norvir (ritonavir) and Kaletra (lopinavir/ritonavir). More recently, Dale co-directed AbbVie’s hepatitis C discovery program leading to the development of Viekira Pak (dasabuvir/ombitasvir/paritaprevir/ritonavir) and Mavyret (glecaprevir/pibrentasvir). Dale has published widely in areas of medicinal chemistry, pharmacology and rug resistance, and has received several awards, including the 1997 Intellectual Property Owners Association National Inventor of the Year Award, the 1999 Pharmaceutical Research and Manufacturers of America Discoverers Award, the 2003 American Chemical Society Heroes of Chemistry Award, and the 2010 David Berry HIV DART Achievement Award. Currently he coordinates the Neglected Diseases program at AbbVie, a cross-functional effort to work alongside partners dedicated to the discovery and development of new therapies for underserved populations. Dale serves on the Scientific Advisory Boards for the Global Alliance for TB Drug Development (TB Alliance) and Drug for Neglected Diseases initiative (DNDi).
Associate Professor of Research in Microbiology and Immunology
Weill Cornell Medical College
Ben Gold is an Associate Research Professor at Weill Cornell Medical College where he is leading an antibiotic discovery program to identify compounds that kill non-replicating Mycobacterium tuberculosis and their targets. Dr. Gold was an Assistant Professor and Postdoctoral Associate, also at Cornell. Dr. Gold holds a PhD in Microbiology from NYU and studied at the Pasteur Institute, Indiana University, and the University of Strasbourg. Dr. Gold is a key participant in the TBDA (TB Drug Accelerator), working with many industrial, academic, and non-profit collaborators.
Senior Program Officer
Bill and Melinda Gates Foundation (BMGF)
Peter Warner is a Senior Program Officer in Discovery and Translational Sciences at the Bill & Melinda Gates Foundation, Seattle, Washington, USA. He joined the Bill & Melinda Gates Foundation in 2013 after a 28-year career in the pharmaceutical industry. Trained as a medicinal chemist, he has worked across a broad range of therapy areas delivering drug candidates to the clinic. Immediately before joining the Bill & Melinda Gates Foundation he led the AstraZeneca Neglected Diseases Research Unit in Bangalore, India. He currently manages a portfolio of drug discovery grants focused on tuberculosis, malaria and filarial diseases and co-leads the Tuberculosis Drug Accelerator consortium.
Translated with Google Translate